Related Experiment Video
Updated: Jul 9, 2026
06:58
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
The burden of dementia
1School of Nursing, University of Pennsylvania, 420 Guardian Dr, Philadelphia, PA 19104, USA. cottervt@nursing.upenn.edu
The American Journal of Managed Care
|January 12, 2008
Summary
Effective dementia care requires distinguishing between Alzheimer's disease and other dementias. Nonpharmacologic interventions in long-term care facilities can improve outcomes for dementia patients by managing risks and promoting pain-free, restraint-free environments.
Area of Science:
- Gerontology and Geriatric Medicine
- Neurology
- Healthcare Management
Background:
- Rising prevalence of Alzheimer's disease (AD) and related dementias presents significant economic and medical challenges.
- Dementia patients in long-term care (LTC) face heightened risks of adverse outcomes compared to non-demented residents.
Purpose of the Study:
- To emphasize the importance of differentiating common dementing illnesses: AD, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies.
- To highlight strategies for assessing and managing risk factors in LTC dementia patients.
- To present nonpharmacologic interventions for improving care quality in LTC settings.
Main Methods:
- Review of common dementia types and their differentiating signs and symptoms.
- Analysis of risks associated with dementia in LTC, including functional decline and behavioral issues.
- Identification and description of specific nonpharmacologic interventions for LTC.
Main Results:
- Accurate diagnosis is crucial for effective dementia care and management.
- Active assessment and management of risk factors can improve outcomes for LTC dementia residents.
- Nonpharmacologic strategies can promote restraint-free and pain-free care.
Conclusions:
- Differentiating dementia types is essential for appropriate patient care.
- Proactive risk management and targeted nonpharmacologic interventions are key to enhancing the quality of life for individuals with dementia in long-term care settings.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...